Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
Phase 4
250
about 2.3 years
12–80
55 sites in CA, CO, FL +20
What this study is about
This trial is testing whether adding dupilumab to a medium dose inhaled corticosteroid/long-acting beta-agonist (ICS/LABA) is more effective than increasing the dose of the inhaled corticosteroid/long-acting beta-agonist (ICS/LABA). It involves adults and adolescents with uncontrolled asthma who are not responding well to their current asthma medications. The goal is to determine which treatment approach provides better control of asthma symptoms.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take ICS/LABA
- 2.Take Matching Placebo
- 3.Take dupilumab
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
dupilumab
Secondary: Change in FEV1: FVC ratio, Change in percent predicted FEV1, Change in post-bronchodilator FEV1, Change in pre-bronchodilator FEV1, Change in pre-bronchodilator Forced expiratory volume in the first second (FEV1), Incidence of Treatment-emergent adverse event (TEAEs)
Respiratory